This invention relates to the extraction of psychoactive compounds from psilocybin fungus for use in medicine. Raw psilocybin fungus is dried and ground. The solvent used for extraction is a lower aliphatic alcohol, water, a hydro-alcohol mixture, an acidic hydro-alcohol mixture, or an alkaline hydro-alcohol mixture. The extraction slurry is filtered and pH-adjusted if necessary. The solvent is then partially evaporated, or completely evaporated with water added back, to form a concentrated slurry. The concentrated slurry is then standardized to provide a known concentration of the psychoactive alkaloids that have been extracted. The standardized slurry may then be dried to result in a powdered psilocybin mushroom extract with a precisely defined purity.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

Compositions and methods for promoting skin restoration of aging skin are provided herein. Compositions and methods described herein may result in elastin and/or collagen stimulation, extracellular matrix (ECM) recycling, anti-inflammatory effects, or combinations thereof.

Compositions and methods for promoting skin restoration of aging skin are provided herein. Compositions and methods described herein may result in elastin and/or collagen stimulation, extracellular matrix (ECM) recycling, anti-inflammatory effects, or combinations thereof.

The present invention relates to stable formulations of recombinant proteins. The invention specifically relates to the formulations of recombinant lectins derived from Sclerotium rolfsii lectin. The formulation comprises recombinant lectin derived from Sclerotium rolfsii lectin and a pharmaceutically acceptable excipient. The invention also relates to the stable liquid and/or lyophilized formulations comprising recombinant lectins derived from Sclerotium rolfsii lectin.

The present invention relates to stable formulations of recombinant proteins. The invention specifically relates to the formulations of recombinant lectins derived from Sclerotium rolfsii lectin. The formulation comprises recombinant lectin derived from Sclerotium rolfsii lectin and a pharmaceutically acceptable excipient. The invention also relates to the stable liquid and/or lyophilized formulations comprising recombinant lectins derived from Sclerotium rolfsii lectin.

Provided is a composition for oral administration, which can include a combination of an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus, and at least one of a cannabis oil or a cannabinoid and optionally, a material comprising a surfactant or an oil, and wherein the composition has a reduced undesirable taste compared with the same composition lacking the extracellular portion. Also provided is a method for reducing undesirable tastes in a composition comprising a cannabinoid or cannabis oil for oral administration, which include adding an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus to the cannabinoid-containing or cannabis oil-containing product for oral administration in an amount sufficient to reduce at least one undesirable taste in the composition.

Provided is a composition for oral administration, which can include a combination of an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus, and at least one of a cannabis oil or a cannabinoid and optionally, a material comprising a surfactant or an oil, and wherein the composition has a reduced undesirable taste compared with the same composition lacking the extracellular portion. Also provided is a method for reducing undesirable tastes in a composition comprising a cannabinoid or cannabis oil for oral administration, which include adding an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus to the cannabinoid-containing or cannabis oil-containing product for oral administration in an amount sufficient to reduce at least one undesirable taste in the composition.